Cabazitaxel-XRP6258-DataSheet-MedChemExpress_第1頁
Cabazitaxel-XRP6258-DataSheet-MedChemExpress_第2頁
Cabazitaxel-XRP6258-DataSheet-MedChemExpress_第3頁
Cabazitaxel-XRP6258-DataSheet-MedChemExpress_第4頁
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemECabazitaxelCat. No.: HY-15459CAS No.: 183133-96-2Synonyms: XRP6258; RPR-116258A; taxoid XRP6258分式: CHNO分量: 835.93作靶點(diǎn): Microtubule/Tubulin; Autophagy作通路: Cell Cycle/DNA Damage; Cytoskeleton; Autophagy儲存式: Powder -20C 3 years4C 2

2、yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 100 mg/mL (119.63 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.1963 mL 5.9814 mL 11.9627 mL5 mM 0.2393 mL 1.1963 mL 2.3925 mL10 mM 0.1196 mL 0.5981 mL 1.1963 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請

3、注意儲備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請根據(jù)您的實(shí)驗(yàn)動物和給藥式選擇適當(dāng)?shù)娜芙獍福渲魄罢埾扰渲瞥吻宓膬湟?,再依次添加助溶?為保證實(shí)驗(yàn)結(jié)果的可靠性,體內(nèi)實(shí)驗(yàn)的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄清的儲備液可以根據(jù)儲存條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占):1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (2.99 mM); Clear solution2. 請依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubili

4、ty: 2.5 mg/mL (2.99 mM); Clear solution1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE3. 請依序添加每種溶劑: 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (2.99 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Cabazitaxel天然紫杉烷脫酰 巴卡丁III的半合成衍物,具有顯著的抗腫瘤功效。體外研究 The cytotoxicity of cabazitaxel (100 g/mL) on 4T1 cells wit

5、hout irradiation is 70.8%. Cabazitaxel (100 g/mL)exhibits a concentration-dependent antiproliferation effect, with the antiproliferative activity of 56.2% 1.體內(nèi)研究 Cabazitaxel (10 mg/kg, i.v.) has certain toxicity to liver and kidney but it can be avoided by integrated intoAns. The body weights of mic

6、e treated with AN-ICG-CBX and AN-CBX have a slightly decrease, while bodyweights of the free CBX group significantly decrease compared to the control group 1.PROTOCOLCell Assay 1 The cytotoxicity of CBX-loaded ANs and free Cabazitaxel (CBX) is evaluated with MTT assay. Cells areseeded onto a 96-well

7、 plate at a density of 3000 cells per well and cultured for 24 h. CBX-loaded ANs andfree CBX are diluted to predetermined concentrations with PBS and added into each well. Blank AN, AN-ICGand free CBX solvent (a mixture of Tween-80 and anhydrous alcohol) are added as well to different finalconcentra

8、tions. The incubation continued for another 48 hours. 20 L MTT solutions (5 mg/mL in PBS) areadded into each well and cells are incubated for another 4 hours under 37C. Subsequently the medium isremoved and 150 L dimethyl sulphoxide (DMSO) is added to dissolve the purple formazan salt crystals.Then

9、the absorbance is measured by a microplate reader at 490 nm. The cells treated with medium areevaluated as controls.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal To evaluate the antitumor efficiency of the combined chemotherapy and PTT in vivo,

10、 mice bearing 4T1 tumorAdministration 1 are randomLy divided into 6 treatment groups (n=5). Treatment begin when the tumors reached 50 mm3-100mm3. The mice are intravenously injected with saline, AN-ICG, free Cabazitaxel (CBX), AN-CBX and AN-ICG-CBX (ICG 2 mg/kg, CBX 10 mg/kg). 8 hours later, the gr

11、oups injected with AN-ICG and AN-ICG-CBX isirradiated by the 808 nm laser (0.8 W/cm2, 5 min). The length and width of every tumor are measured by acaliper every other day. The formula (volume (mm3) =1/2 length width2) is used to calculate the tumorvolume. The body weights of these mice are recorded

12、every two days using an electronic balance as well. Atthe end of the antitumor study, the 4T1 tumor bearing mice are sacrificed to collect the tumors and majororgans.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Nanomedicine (Lond). 2017 S

13、ep;12(17):2083-2095. Chin J Cancer. 2015 Mar 5;34(3):115-20.2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE Prostate. 2018 Sep;78(12):905-914. Prostate. 2018 Feb;78(3):166-177. Methods Mol Biol. 2018;1711:351-398.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Tai X, et al. C

14、abazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimizeddrug toxicity. J Drug Target. 2016 Sep 9:1-29.2. Gdowski AS, et al. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine(Lond). 2017 Sep;12(17):

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

最新文檔

評論

0/150

提交評論